Crinetics Pharmaceuticals Inc. Overview

Crinetics Pharmaceuticals Inc., a clinical-stage pharmaceutical company headquartered in San Diego, California, is making strides in the biotechnology sector. The company is dedicated to developing innovative therapeutics aimed at treating endocrine diseases and cancers. With a mission to revolutionize healthcare, Crinetics focuses on providing groundbreaking solutions for chronic conditions.

Financial Snapshot

As of May 8, 2025, Crinetics Pharmaceuticals Inc. had a close price of $30.68 on the Nasdaq, where it is primarily listed. The company’s market capitalization stands at approximately $3.14 billion. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $62.53 on November 13, 2024, and a 52-week low of $24.10 on April 8, 2025. The price-to-earnings ratio is currently at -9.05, reflecting the company’s ongoing investment in research and development without immediate profitability.

Industry and Sector

Operating within the health care sector, Crinetics Pharmaceuticals Inc. is part of the biotechnology industry. The company’s focus on endocrine diseases and cancers positions it at the forefront of therapeutic innovation, addressing some of the most challenging medical conditions.

Mission and Goals

Crinetics Pharmaceuticals Inc. is committed to transforming the healthcare landscape by developing cutting-edge treatments. The company’s strategic focus on endocrine and cancer therapies underscores its dedication to addressing unmet medical needs and improving patient outcomes.

In summary, Crinetics Pharmaceuticals Inc. continues to pursue its mission of revolutionizing healthcare through innovative therapeutic solutions, despite the financial challenges typical of a clinical-stage biotechnology company.